EHA 2017 | Midostaurin: a step forward in the treatment of FLT3-mutated AML
Mark Levis
• 22 Jun 2017
Mark Levis, MD, PhD, from John Hopkins University, Baltimore, MD, USA, talks to us about the recent approval of the FLT3 inhibitor, midostaurin, in the US, and its importance in being incorporated into the standard of care for FML-mutated patients with acute myeloid leukemia (AML). He adds that there are currently six Phase III trials in progress that are investigating a number of FLT3 inhibitors and he believes that there will be a steady influx of these agents entering medical practice over the next 5 years. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
